Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification

Nicholas J. Izzo, Carla M. Yuede, Kelsie M. LaBarbera, Colleen S. Limegrover, Courtney Rehak, Raymond Yurko, Lora Waybright, Gary Look, Gilbert Rishton, Hank Safferstein, Mary E. Hamby, Claire Williams, Kelsey Sadlek, Hannah M. Edwards, Charles S. Davis, Michael Grundman, Lon S. Schneider, Steven T. DeKosky, Daniel Chelsky, Ian PikeChristopher Henstridge, Kaj Blennow, Henrik Zetterberg, Harry LeVine, Tara L. Spires-Jones, John R. Cirrito, Susan M. Catalano

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Fingerprint

Dive into the research topics of 'Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Neuroscience